Last reviewed · How we verify
MLN518
At a glance
| Generic name | MLN518 |
|---|---|
| Sponsor | Millennium Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer (PHASE2)
- Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma (PHASE1, PHASE2)
- Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors (PHASE2)
- Tandutinib in Treating Patients With Progressive Prostate Cancer and Bone Metastases (PHASE2)
- A Phase 2 Study of Tandutinib in Patients With Newly Diagnosed Acute Myelogenous Leukemia Who Are Considered Ineligible For or Who Decline Treatment With Standard Induction Therapy (PHASE1, PHASE2)
- Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme (PHASE1)
- Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) (PHASE1)
- MLN518 in Combination With Standard Induction Chemo. for Treatment of Patients With Newly Diagnosed Acute Myelogenous Leukemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MLN518 CI brief — competitive landscape report
- MLN518 updates RSS · CI watch RSS
- Millennium Pharmaceuticals, Inc. portfolio CI